Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens
Yoon‐Koo Kang, W. Kang, Maria Di Bartolomeo, Ian Chau, Harry H. Yoon, Stefano Cascinu, Min‐Hee Ryu, J.G. Kim, K.-W. Lee, Sang Cheul Oh, Atsuo Takashima, Anna Kryzhanivska, Yee Chao, Vladimir Vladimirov, Ludovic Evesque, Michael Schenker, Aileen McGinn, Neil Sankar, Lucjan Wyrwicz, Narikazu Boku
Annals of Oncology, 2019
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.